Wall Street analysts forecast that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will post earnings per share (EPS) of $1.25 for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for AMAG Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $1.31 and the lowest estimate coming in at $1.19. AMAG Pharmaceuticals posted earnings of $1.78 per share during the same quarter last year, which would indicate a negative year over year growth rate of 29.8%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that AMAG Pharmaceuticals will report full-year earnings of $4.93 per share for the current fiscal year, with EPS estimates ranging from $4.60 to $5.23. For the next year, analysts expect that the business will post earnings of $1.88 per share, with EPS estimates ranging from $0.86 to $2.80. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover AMAG Pharmaceuticals.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The business had revenue of $158.39 million for the quarter, compared to the consensus estimate of $158.83 million. During the same period last year, the company earned $1.45 EPS. The firm’s revenue was up 24.3% compared to the same quarter last year.

A number of equities analysts have issued reports on AMAG shares. Cantor Fitzgerald restated a “hold” rating and issued a $23.00 price objective on shares of AMAG Pharmaceuticals in a research report on Monday, June 26th. BidaskClub raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Citigroup Inc. lowered their price objective on AMAG Pharmaceuticals to $24.00 and set a “hold” rating for the company in a research report on Friday, July 7th. Deutsche Bank AG set a $24.00 price target on shares of AMAG Pharmaceuticals and gave the company a “hold” rating in a research report on Friday, July 7th. Finally, Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 target price for the company in a report on Tuesday, July 11th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $27.75.

In other news, SVP Julie Krop sold 4,938 shares of the company’s stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $20.00, for a total transaction of $98,760.00. Following the transaction, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at $566,720. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 3.80% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Great West Life Assurance Co. Can lifted its holdings in shares of AMAG Pharmaceuticals by 3.8% during the first quarter. Great West Life Assurance Co. Can now owns 46,746 shares of the specialty pharmaceutical company’s stock worth $1,052,000 after purchasing an additional 1,724 shares during the period. First Trust Advisors LP lifted its holdings in AMAG Pharmaceuticals by 49.5% in the first quarter. First Trust Advisors LP now owns 55,055 shares of the specialty pharmaceutical company’s stock valued at $1,241,000 after acquiring an additional 18,227 shares during the period. Advisors Asset Management Inc. lifted its holdings in AMAG Pharmaceuticals by 259.9% in the first quarter. Advisors Asset Management Inc. now owns 6,931 shares of the specialty pharmaceutical company’s stock valued at $156,000 after acquiring an additional 5,005 shares during the period. Comerica Bank lifted its holdings in AMAG Pharmaceuticals by 4.5% in the first quarter. Comerica Bank now owns 38,047 shares of the specialty pharmaceutical company’s stock valued at $936,000 after acquiring an additional 1,648 shares during the period. Finally, Karp Capital Management Corp purchased a new stake in AMAG Pharmaceuticals in the 1st quarter worth approximately $232,000.

Shares of AMAG Pharmaceuticals (AMAG) traded down 2.06% during mid-day trading on Tuesday, reaching $19.05. The company had a trading volume of 808,248 shares. AMAG Pharmaceuticals has a 12-month low of $16.00 and a 12-month high of $36.83. The firm’s market capitalization is $672.24 million. The stock has a 50 day moving average price of $18.19 and a 200 day moving average price of $19.48.

TRADEMARK VIOLATION WARNING: This article was published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/10/03/1-25-eps-expected-for-amag-pharmaceuticals-inc-amag-this-quarter.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.